News | July 18, 2022
Glaucoma Research Foundation launches catalyst for a to prevent and cure neurodegeneration
Groundbreaking collaborative research program will explore common characteristics of glaucoma, alzheimer's
Groundbreaking collaborative research program will explore common characteristics of glaucoma, alzheimer's
LHP588 is an oral, brain-penetrant lysine-gingipain (Kgp) inhibitor designed to block the key virulence factor of P. gingivalis
Usnoflast has previously also received ‘Orphan Drug Designation (ODD)’ from the USFDA
New trontinemab data continue to support rapid and deep, dose-dependent reduction of amyloid plaques in Phase Ib/IIa Brainshuttle AD study
The first-of-its-kind study will evaluate potential association between GSK’s shingles vaccine and reduced dementia risk, building on growing body of evidence from observational and retrospective studies
The company is committed to unlocking new frontiers in neuroscience and developing Usnoflast for patients with ALS
This study will enrol 210 ALS patients and study doses of 50 mg and 75 mg Usnoflast versus placebo
ALS patients experience neuroinflammation and rapid neurodegeneration
ALS is a rare, progressive and fatal neurodegenerative disease, with an average life expectancy of 3 to 5 years from the time of symptom onset
GC1130A has previously achieved notable milestones by securing both RPDD and ODD from the U.S. FDA in January 2023
Subscribe To Our Newsletter & Stay Updated
